1 Min Read
Dec 15 (Reuters) - Mesoblast Ltd:
* HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.